Current Studies

SURMOUNT-2

Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight:

Checking Weight
 Closed

Type of Study:
A Randomized, Double- Blind, Placebo-Controlled Trial for weight maintenance or weight loss for participants who have obesity or are overweight with weight-related diseases.

Study Length:
Approximately 79 weeks (22 visits)

Target Age/Sex:
over 18 years, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Staus: Enrolling

Description:

This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight.

TRAVERSE

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events and Efficacy Measures in Hypogonadal Men

Type of Study:
Blinded placebo controlled of topical Testosterone replacement therapy

Study Length:
5 years

Target Age/Sex:
45 - 80, Male

Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.

Link: ClinicalTrials.gov

Staus: Enrolling

Description:

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events and Efficacy Measures in Hypogonadal Men

Man in Nature
 Closed

ANJ900D3501

A randomized, multicenter, double-blind, parallel-group, placebo- and comparator-controlled study to compare the glycemic effects, safety, and tolerability of Metformin hydrochloride delayed-release tablets in patients with type 2 Diabetes Mellitus with varying renal function from normal up to CKD3b

Prescription Drugs
Enrolling

Indication:

Type 2 diabetes mellitus (T2DM) with estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2

Study Length:
Approximately 52 weeks (22 visits)

Target Age/Sex:
over 18 years, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Staus: Enrolling

Description:

This is a Phase 3, 52-week, multicenter study with a 28-week, randomized, double-blind, parallel-group, placebo- and comparator-controlled treatment period (Double-Blind Treatment Period) and 24-week, open-label extension period (Open-Label Extension Period) that will be conducted in approximately 675 patients with T2DM with varying renal function from normal up to CKD3B who are treated with metformin preparation at the time of study screening.

STABILIZE-CKD

Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants with CKD and Hyperkalemia or at Risk of Hyperkalemia

Type of Study:  A Phase 3, International, Randomized, Double-Blind,
Placebo Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Patients with CKD and Hyperkalemia or at Risk of Hyperkalemia 

Study Length:
28 months

Target Age/Sex:

over 18 years, Male and Female

Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.

Link: https://clinicaltrials.gov/ct2/show/NCT05056727

Staus: Enrolling

Description:

This is a Phase 3, international, randomised withdrawal, double-blind, parallel-group, placebo-controlled study, to evaluate the effect of SZC as adjunct to RAASi therapy (lisinopril or valsartan) in slowing CKD progression in participants with CKD and hyperkalaemia or at risk of hyperkalaemia.

Specifically, the study will include participants with hyperkalaemia (S-K > 5.0 to ≤ 6.5 mmol/L by central laboratory) who are on adequate or limited RAASi therapy due to hyperkalaemia, and participants with normokalaemia (S-K ≥ 3.5 to ≤ 5.0 mmol/L by central laboratory) who are on limited RAASi therapy due to high risk of hyperkalaemia. High risk of hyperkalaemia is defined as (1) participants with a previous medical history or record of hyperkalaemia within the prior 24 months who are on limited RAASi therapy despite indication in CKD; (2) participants in whom RAASi therapy is indicated in CKD but are on limited RAASi therapy and have S-K ≥ 4.7 to ≤ 5.0 mmol/L; and (3) participants in whom RAASi therapy has been discontinued or reduced to suboptimal doses because of hyperkalaemia.

crystalize.jpg
lokelma_edited.jpg
Enrolling
fda approved.png